Oct. 16, 2025 -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the investigational new drug (“IND”) application for an open-label, two-arm, randomized, active-controlled, phase 2/3 clinical study comparing the company’s product, recombinant humanized anti-PD-1/VEGF bispecific antibody (code: JS207), to nivol

Oct. 16, 2025 -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming poster presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 in Boston, MA. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on

Covers low tumor burden “watch-and-wait” setting, an unmet medical need Registrational Phase 3 watch-and-wait to start in 2026 EO2463 has broad potential to treat hemato-oncology indications 16 OCTOBER, 2025 Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for follicular lymphoma in the low tumor burden “watch-and-wait” setting for its lead

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments in refractory Herpes Simplex Virus (HSV) infected immunocompromised patients Pritelivir was well tolerated and had a favorable safety profile over the treatment duration Full results will be presented at an upcoming medical conference and will form the basis for regulatory filings with the FDA and g

On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy designed to pair targeted B-cell control with active anti-inflammatory signaling and pathogenic T-cell modulation in a CNS-penetrant package $50 million in venture financing extends cash runway into 2027, allowing Tr1X to advance the TRX319 Phase 1/2a study and the ongoing TRX103 Phase 1/2a trial for patients with refractory Crohn’s disease Oct. 14, 2025 -- Tr1X, a clini

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Demonstrated superior inhibition of pDCs vs. litifilimab in vitro and superior Ig reductions vs. povetacicept in NHPs highlight the potential for improved clinical benefit in severe autoimmune diseases DNTH212 has the potential to be a first line biologic in multiple autoimmune disorders with pati

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1 eGFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients1-3 Fabhalta is first and only approved complement inhibitor for adults with IgAN and has potential to delay disease progression4,5 Fabhalta received accelerated approval fo

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary endpoint, of 4.3 points (p<0.0001) All key secondary endpoints in Study 1 - rate of disease improvement over 12 weeks, PGI-C and CGI-S - were also statistically significant (p<0.001) Study 2 met its pre-specified primary endpoint, with patients showing superior maintenance of effect while on ul

BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510 Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to re-potentiate apoptosis in highly aggressive tumor type Oct. 16, 2025 -- BPGbio Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that it will present two posters on its lead investigational drug BPM31510 for

– Financing led by new investor Bain Capital Private Equity with participation from new and existing investors to support continued development of a differentiated, late-stage portfolio of obesity treatments – – Proceeds support advancement of KAI-9531, an injectable GLP-1/GIP dual agonist with potentially best-in-category weight loss, to global Phase 3 trials by year end – – Kailera continues to progress clinical development across its broader pipeline of oral and injectable obesity therapies –